As precision medicine demands molecular determinants of drug response, CellMinerCDB provides (https://discover.nci.nih.gov/cellminercdb/) a web-based portal for multiple forms of pharmacological, molecular, and genomic analyses, unifying the richest cancer cell line datasets (NCI-60, NCI-SCLC, Sanger/MGH GDSC, and Broad CCLE/CTRP). CellMinerCDB enables genomic and pharmacological data queries for identifying pharmacogenomic determinants, drug signatures, and gene regulatory networks for researchers without requiring specialized bioinformatics support. It leverages overlaps of cell lines and tested drugs to allow assessment of data reproducibility. It builds on the complementarity and strength of each dataset. A panel of 41 drugs evaluated in parallel in the NCI-60 and GDSC is reported, supporting drug reproducibility across databases, repositioning of bisacodyl and acetalax for triple negative breast cancer, and identifying novel drug response determinants and genomic signatures for topoisomerase inhibitors and schweinfurthins in development. CellMinerCDB also allowed the identification of LIX1L as a novel mesenchymal gene regulating cellular migration and invasiveness.
To unleash the power of integrative analyses within and across data sources, we have developed CellMinerCDB (https://discover.nci.nih.gov/cellminercdb/), a web application allowing immediate, interactive exploration of cancer cell line pharmacogenomic data ( Figure 1 ). In CellMinerCDB, named entities are transparently matched across sources, allowing cell line molecular features and drug responses to be readily compared using bivariate scatter plots and correlation analyses. Multivariate models of drug response or any other genomic cell line attribute can be assessed. Analyses can be restricted to tissues of origin, with cell lines across all sources mapped to a uniform tissue type hierarchy. Gene pathway annotations allow assessment and filtering of analysis results. Moreover, CellminerCDB is built using the publicly available rcellminer R/Bioconductor package, which provides analyses and a standard data representation format (8) . The latter also allows CellMinerCDB to be readily updated to include additional data.
In this report, we present CellMinerCDB and key features of molecular and drug data reproducibility, and complementarity across sources. We provide examples illustrating cancer biology explorations and drug response determinants. These include multivariate modeling of the response to topoisomerase inhibitors and to Schweinfurthins, a class of NCI-developed compounds derived from natural products with novel mechanism of action. CellMinerCDB also provides phenotypic signatures for cancer cell lines, including a gene expression-based measure of epithelial-to-mesenchymal (EMT) transition status. We use the latter to assess EMT stratification within specific tissues of origin, and to identify a novel EMT gene, LIX1L.
Detailed use of CellMinerCDB is described in a video tutorial (https://youtu.be/2HicAgcyJHI).
Results
Data source comparisons. CellMinerCDB integrates four prominent cancer cell line data sources (CellMiner NCI-60 (2, (8) (9) (10) , Sanger/Massachusetts General Hospital GDSC (3), the Broad/Novartis CCLE, and the Broad CTRP) (5, 6 ) and a tissue-specific dataset encompassing 66 small cell lung cancer lines (NCI SCLC) (11) (Figure 1 ). Collectively, these sources provide drug activity and molecular profiling data for approximately 1,400 distinct cancer cell lines (Figure 1b , Supplementary Data). Each source has particular strengths. The NCI-60 is unmatched with respect to breadth of molecular profiling data, as well as the number of tested drugs. The NCI-60 data also include replicate data readily accessible via the established CellMiner data portal (2) . The GDSC, CCLE, and CTRP sources feature much larger numbers of cell lines, spanning tissues of origin not included in the NCI-60. The range of tested compounds in these expanded cell line panels is narrow relative to the NCI-60, though the GDSC and CTRP focus on a wide range of clinically relevant anticancer drugs. The CTRP provides data for 170 FDA-approved or investigational anticancer drugs and 196 other compounds with mechanism of action information. The CTRP molecular data in CellMinerCDB are from the CCLE (Figure 1b ).
Despite ongoing data acquisition and processing efforts, gaps exist with respect to genomic profiling data in sources other than the CellMiner NCI-60 (Figure 1b, dark grey table entries). For the GDSC gene mutation and methylation data, we took advantage of processing pipelines developed for the NCI-60 (10, 12) to compute gene-level summary data from publicly available raw data. Remaining source-specific molecular profiling data gaps can be filled within CellMinerCDB by effectively extending data provided by one source to another. This is possible because of extensive overlaps between tested cell lines and drugs (Figures 1c-f ). For example, methylation data are not publicly available for the CCLE, but GDSC methylation data are available for the matching 671 cell CCLE lines and 597 CTRP lines (Figure 1c Readers are invited to explore their own queries at https://discover.nci.nih.gov/cellminercdb/ by selecting a genomic feature for any given gene in two different datasets of their choice.
Gene-level mutation data in CellMinerCDB indicate the probability that an observed mutation is homozygous and is function impacting. These values were converted to cumulative probability values for genes with multiple deleterious mutations (12) , and are available in graphical and tabular forms at https://discover.nci.nih.gov/cellminercdb/. To compare gene-specific mutation profiles across sources, we binarized the matched cell line data by assigning a value of 1 to lines with an aforementioned probability value greater than 0.3. Entirely matched mutation profiles across sources should have a Jaccard index value of 1. As such, the similarity index distributions indicate greater discordance for the mutation data Indeed, the Jaccard similarity values approaching 1 with the NCI-60 comparisons often derive from just one or two matched mutant cell lines. We used similar processing steps to derive gene-level mutation data from variant call data for the NCI-60, GDSC, and CCLE (Materials and Methods). Still, differences between the underlying sequencing technologies and initial data preparation methods across the sources may account for some of the observed discrepancies. For example, the CCLE mutation data were obtained for a selected set of 1,667 cancer-associated genes subject to high-depth exome capture Table 1 ). For the tumor suppressors, we binarized the data using a probability threshold of 0.7 (to account for the recessive nature of such mutations), while for the oncogenes, the threshold of 0.3 was retained (to account for the dominance of oncogene activating mutations). The most frequently mutated genes were TP53, KRAS, BRAF, APC, RB1, NF1, PTEN, SMARCA4 and MLH1 (Supplementary Table 1 ). BRAF mutation profiles showed substantial overlap (J > 0.7) across all source comparisons, as was the case for the TP53 gene across the GDSC and CCLE (J = 0.69). On the other hand, PIK3CA, BRCA2, BRCA1 and MLH1, MSH6 and MSH2 mutation comparisons were largely divergent. These discrepancies reflect the ongoing challenges and tradeoffs with mutation profiling technologies and mutation calling procedures.
The ability of CellMinerCDB to compare and integrate data across sources highlights the fundamental research efforts and technological standards still required for accurate identification of mutations.
Drug activity data reproducibility and enrichment. Recent studies have examined the issue of drug data reproducibility, noting potential sources of data divergence such as assay type and duration of drug treatments (13) (14) (15) . To explore reproducibility and enrich for genomic signatures, we tested a selected set of NCI-60-screened compounds for activity in the larger GDSC panel (Supplementary Table 2 . These FDAapproved laxatives were included in our comparative analysis due to their outstanding activity in two of the three triple-negative breast cancer cell lines of the NCI-60, and the lack of pre-existing data in the CTRP, CCLE and GDSC. The GDSC results confirm that acetalax and bisacodyl elicit a broad range of cytotoxic responses in the expanded GDSC cell line collection, and extend our NCI-60 observations, being more active than any of the 15 tested oncology drugs by a significant margin (p < 7 x 10 -10 ) in the 22 GDSC triple-negative breast cancer lines (Supplementary Table 3 ).
The non-camptothecin indenoisoquinoline-based topoisomerase I inhibitor in clinical trial, LMP744 (NSC 706744; MJ-III-65) (16, 17) , was also included in our 19-compound test set to assess the similarity of its activity profile with that of topotecan over a larger cell line collection and enrich the genomic signature Table   2 ). Difficulties with the assay were evident for the three drugs with more discrepant activity data.
Dacarbazine, an alkylating agent related to temozolomide, and vincristine, an anti-tubulin, both had poor reproducibility even within DTP assay replicates, while the DTP assay for fulvestrant appeared to be out Table 4 ). The impact of copy gain on increased oncogene expression can be similarly assessed with CellMinerCDB. Figure 4g shows that a subset of MYC-driven CCLE small cell lung cancer lines exhibit both MYC copy gain and increased MYC gene expression. KRAS activation, typically regarded as mutation-driven, also occur by copy gain, as evidenced in a subset of CCLE lines (Figure 4h ), as well as in clinical studies (18) .
Exploring drug response determinants. CellMinerCDB provides correlation analyses and scatter plots for testing and visualizing potential response-determinant relationships (univariate analyses) as well as multivariate linear regression methods for integrating multiple determinants (multivariate analyses; see
Figures 5d and 6b). CellMinerCDB also retrieves significant candidate genomic determinants as well as drug correlations (compare analysis tool). This type of approach led to the discovery of Schlafen 11 (SLFN11), a new molecular determinant of response to a broad range of widely used DNA-targeted anticancer agents including topoisomerase inhibitors, platinum derivatives, PARP inhibitors and antimetabolites (5, 19) . CellMinerCDB allows users to quickly assess the generality of results presented in the literature, and iteratively explore evidence for multifactorial mechanistic models. Figure 5a shows an example for indisulam, which targets the splicing factor RBM39 for proteasomal degradation by forming a ternary complex with RBM39 and the E3 ubiquitin ligase receptor DCAF15. A report of increased indisulam sensitivity in hematopoietic cell lines with high DCAF15 expression is readily verified with CellMinerCDB ( Figure 5b, red dots) (20) . CellMinerCDB-integrated pharmacogenomic data also corroborate a report of MYC-driven small cell lung cancer exhibiting vulnerability to aurora kinase inhibition (21) (Figure 5c ).
Multivariate model development without bioinformatics assistance is illustrated for the topoisomerase II inhibitor etoposide (Figure 5d-g ). Starting with expression of the drug target (TOP2A and TOP2B) (22) and SLFN11, an established determinant of response to DNA-targeted drugs (19, 23, 24) , the user can select additional determinants based on biological knowledge. Determinant selection can be further guided by pathway annotations and partial correlation analyses, which rank additional features by their capacity to improve the current model (Figure 5g ). Figures 3b-d) . Experimental analyses in knockout cell lines revealed that LIX1L is inversely connected with cell migration and invasiveness (Figure 7f-h, Supplementary Figures 3c, d ).
We also correlated the EMT index with GDSC activity profiles for 297 compounds (Supplementary Figure 4b) . The second strongest negative correlate with the EMT index was the RHO-associated kinase 1 inhibitor GSK269962A (Supplementary Figure 4b) , whose target participates in the regulation of actin dynamics and cell motility during the EMT (32, 33) .
Discussion
CellMinerCDB allows researchers to interact freely with an unparalleled breadth of cancer cell line pharmacogenomic data, using their expertise to iteratively refine analyses. Our results, spanning data assessment, integration, and discovery demonstrate the value of working across data sources. They support the maturity and essential reproducibility of most molecular profiling technology platforms, such as gene transcript expression, copy number, and methylation.
Mutation data are prominently featured in translational studies, and CellMinerCDB exposes the issue of discrepancies between matched cell line mutation profiles across sources. This provides a foundation for understanding and mitigating sources of variability, which reflect the ongoing technical challenges and tradeoffs with acquiring genome sequencing data. Somatic variant calling in cancer cell lines is inherently challenging due to the absence of matched normal tissue for comparison, as well as the potentially higher mutation burden in cell lines relative to primary tumor tissue. In this setting, variability in cell line mutation data across sources may additionally arise from differences in variant calling algorithms, as well as data sources used for filtering likely germline variants. One approach for excluding potentially cell line-specific passenger mutations is to filter variants based on frequency in patient populations (4).
Another strategy for more robust mutation data is to pursue higher depth targeted sequencing of a restricted gene set. Indeed, we noted that CCLE data, derived from the latter sort of approach, consistently identified more mutant cell lines for prominent oncogenes and tumor suppressor genes than genome-wide exome sequencing (as in the NCI-60 and GDSC databases). Nevertheless, using CellMinerCDB, researchers can quickly integrate mutation data across sources to identify cell lines with consistent mutation calls for a gene of interest, together with other potentially impacted lines.
Drug response assays used across the major pharmacogenomic data sources measure different biochemical features over different time scales. Still, CellMinerCDB demonstrates significant concordance between activity data generated at the NCI and the Sanger Institute. Moreover, for several widely used anticancer drugs, such as topotecan and dabrafenib, we observed activity data reproducibility across all major sources. We expanded the data available for understanding variability in drug activity profiling by testing 19 compounds from a range of mechanistic classes in the large GDSC cell line panel.
Readily accessible scatterplots of matched cell line activity data can highlight problem areas with particular assays, such as inappropriate concentration ranges in the case of fulvestrant in the NCI/DTP assay. The cross-database comparison features of CellMinerCDB allow researchers to explore these issues and focus on drugs with reliable data. Among the 19 drugs tested, we found consistent results for most of the drugs and identified bisacodyl and acetalax as potential drug repurposing candidates, being substantially more active in triple-negative breast cancer lines relative to other cancer drugs tested on the GDSC panel.
With both drug activity reproducibility and broader associations between molecular features, such as CDKN2A expression and gene copy/methylation, we noted that the NCI-60 could effectively capture relationships evident in larger cell line sets. The latter better reflects tissue type diversity and associated context-specific molecular features. Still, for dominant associations, such as SLFN11 expression and DNA-targeted drug responses, representative cell line sets such as the NCI-60 are often sufficient (19) .
The NCI-60 provides drug responses for over 21,000 individual agents, making it an unmatched resource for discovery of new chemotypes based on correlations with genomic data and response patterns to drugs with known targets. The NCI databases are also a tractable starting point for molecular data expansion with leading-edge technologies. RNA-Seq data with isoform-specific transcript expression, and SWATH mass spectrometry-based protein expression data have been generated for the NCI-60, and made available within CellMinerCDB (35) .
CellMinerCDB ultimately aims to provide a seamless platform, integrating not just data sources, but the intuition and expertise of experimental scientists and clinicians. The present publication provides only a sample of the potential of CellMinerCDB for focusing translational studies. CellMinerCDB uniquely complements existing data portals that provide detailed information on their associated data, together with specialized analyses. Each source offers unique strengths; for the NCI-60 a broad array of molecular profiling data and the largest set of tested compounds, including potentially novel molecules for drug development, such as the indenoisoquinoline topoisomerase I inhibitors (17) ; for the GDSC, a growing range of molecular and drug activity data over a large cell line panel; for the CTRP, the largest set of tested compounds in a large cell line panel; for the CCLE, high-depth mutation profiling and other molecular data, readily extensible to the CTRP via CellMinerCDB. By empowering researchers to easily build on these strengths and pursue their own questions, CellMinerCDB will advance the potential of cancer cell line pharmacogenomic data to lay the foundation, validate, and focus experimental and ultimately clinical studies.
Methods

CellMinerCDB Implementation
CellMinerCDB was implemented using the R programming language, with interactive features developed using RStudio's Shiny web application framework (https://shiny.rstudio.com/). Underlying analyses and data representations were built with functionality provided by our publicly available rcellminer R/Bioconductor package (8) . For each data source, R data packages were constructed, using software components defined within rcellminer to integrate drug activity data, molecular profiling data, and associated cell line, drug, and gene annotations. This standard data representation allowed diverse data sources to be readily integrated within CellMinerCDB. Source-specific data used in CellMinerCDB data package construction are described in the sections below.
NCI-60 Data
NCI-60 drug activity, molecular profiling, and annotation data was obtained from CellMiner (Database Version 2.1). The latest versions of these data can also be downloaded from https://discover.nci.nih.gov/cellminer/loadDownload.do. Detailed information is provided in (1,9,10,36 ).
Essential attributes made available within CellMinerCDB are summarized below.
Compound activity. Standardized, 'z-score' values were derived from measurement of 50% growthinhibitory (GI50) concentrations using the sulforhodamine B total protein cytotoxicity assay. For each compound, the mean and standard deviation of -log10[molar GI50] values over the NCI-60 lines are used to center and scale the data.
Gene expression. Integration of relevant probe-level data from 5 microarray platforms (1) is provided in both standardized 'z-score' form, derived as described above for the drug activity data, and as average log2 intensities.
Gene-level mutation. The mutation data value for a given gene and cell line is derived from computed probability of a homozygous function-impacting mutation, which is then expressed as a percentage. NCI-60 exome sequencing data was obtained and processed as described (9) . Missense mutations were functionally categorized using ANNOVAR (37) . Missense mutations with a frequency > 0.005 in either the ESP6500 or 1000 Genomes normal population datasets (i.e., potential germline variants) were excluded, together with mutations predicted not to impact protein function by the SIFT and PolyPhen2 algorithms (SIFT > 0.05 or PolyPhen2 HDIV < 0.85 or PolyPhen2 HVAR < 0.85). To obtain a summarized, gene-specific mutation value for each cell line, the probability of both alleles having at least one of the variants was computed. Specifically, let x = (x1, …, xn) be a vector of gene-associated mutation conversion fraction values for a given cell line. The summary gene mutation probability value for this cell line is computed as 1 -(1 -x1) … (1 -xn), and then converted to a percentage value. DNA copy number. DNA copy data were integrated from four array-CGH platforms (36) . Numerical values indicate the average log2 probe intensity ratio for the cell line (gene-specific chromosomal segment) DNA relative to normal DNA.
DNA methylation. Data were obtained using the Illumina Infinium Human Methylation 450 platform as described (10) .Values lie between 0 (lack of methylation) and 1 (complete methylation). microRNA expression. Data were obtained using the Agilent Technologies Human miRNA Microarray V2 (38) . Numerical values indicate average log2 probe intensity.
Protein expression. Reverse phase protein array (RPPA) data were obtained as described (39) . Numerical values indicate probe intensities.
GDSC Data
Compound activity. Preprocessed activity data for 256 compounds were downloaded from http://www.cancerrxgene.org/downloads. GDSC-provided activity values were converted to indicate the -
Gene expression. Raw Affymetrix Human Genome U219 microarray data deposited in ArrayExpress (E-MTAB-3610) were processed using RMA normalization. Probe-to-gene mapping was performed using the BrainArray CDF file for the Affymetrix HG-U219 platform, available at http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/17.1.0/entrezg.download/HGU2 19_Hs_ENTREZG_17.1.0.zip. Numerical values summarize gene-specific log2 probe intensities.
Additional platform and processing details are provided in (4).
Gene-level mutation.
A tab-separated table listing variants detected in GDSC cell lines was downloaded from COSMIC (release v79). Variants indicated as heterozygous and homozygous were assigned values of 0.5 and 1, respectively. After this, gene-level mutation values were computed as described for the NCI-60 mutation data, except that the final, gene and cell line-specific mutation probabilities were retained (rather than converted to percentage values).
DNA methylation. The table of pre-processed beta values for all CpG islands across the GDSC cell lines was downloaded from the supplementary resources site http://www.cancerrxgene.org/gdsc1000/GDSC1000_WebResources/ (4). DNA methylation data were obtained using the Illumina Infinium Human Methylation 450 platform, and gene-level methylation values were computed using the approach utilized with the NCI-60 data (10).
Determination of prospective triple negative breast cancers. Expression levels of ERBB2, ESR1, ESR2
and PGR were assessed by GDSC using the Affymetrix Human Genome U219 Array and accessed in CellMinerCDB. Cell lines with a low value for all 3 genes were classified as triple negative. The log2 intensity thresholds used were ERBB2<5, ESR1< 3.5, and PGR<3.
CCLE Data
CCLE data were downloaded from https://portals.broadinstitute.org/ccle/home (5). Gene expression. Raw CEL file data derived from the Affymetrix U133+2 platform were downloaded from the CCLE portal. Normalization was performed using the frma method, implemented by the corresponding Bioconductor package (40) . Numerical values are the average of gene-specific log2 probe intensities, with the gene-to-probe-set mapping obtained from the hgu133plus2.db Bioconductor package.
Gene-level mutation. The table of targeted sequencing-based mutation data for 1651 genes was downloaded from the CCLE portal. Using the provided allelic fraction information for individual variants, gene-level mutation values were computed as described for the NCI-60.
DNA copy number. Data derived from the Affymetrix SNP 6.0 array were downloaded from the CCLE portal. Numerical values are normalized log2 ratios, i.e., log2(CN/2), where CN is the estimated copy number.
CTRP Data
Activity data for 481 compounds across 823 cell lines were obtained from Supplementary Tables S2, S3, and S4 of reference (6) . Activity data originally indicated as the area under a 16-point dose response curve (AUC) were subtracted from the maximum observed AUC value (over all cell lines and drugs) to represent activity by the estimated area above the dose-response curve. This transformation allows increased drug sensitivity to be associated with larger values of the activity measure, consistent with other source activity data integrated within CellMinerCDB. The above CTRP cell line set is included in the CCLE, and CCLE molecular data are thus used for CTRP analyses in CellMinerCDB.
NCI-SCLC Data
Compound activity and transcript expression data for the NCI-SCLC data set were downloaded from https://sclccelllines-dev.cancer.gov/sclc/downloads.xhtml. Activity values were converted to indicate the - Jaccard coefficient distributions for comparable binary mutation (mut) data. The Jaccard coefficient for a pair of gene-specific mutation profiles is the ratio of the number of mutated cell lines reported by both sources to the number of mutated lines reported by either source. (c, d) Overlaps of function-impacting mutations as predicted using SIFT/PolyPhen2 for selected tumor suppressor genes and oncogenes. Matched cell line mutation data were binarized by assigning a value of one to lines with a homozygous mutation probability greater than a threshold, which was set to 0.3 for (b) and for oncogenes in (c), and to 0.7 for tumor suppressor genes in (d). Reduced mRNA expression (xai, average log2 intensity) of the cell cycle inhibitor and tumor suppressor CDKN2A (p16) is associated with DNA copy loss (cop) (a) and promoter methylation (met) (b) in the NCI-60 lines. In a subset of NCI-60 lines, enclosed in the red box, (c), DNA copy loss accompanies higher levels of promoter methylation. DNA copy number and promoter methylation data from the CCLE and GDSC, respectively, can be also be visualized over matched cell lines to verify a similar pattern in larger cell line collections (d-f). DNA copy number gain is associated with increased expression (exp, z-score microarray log2 intensity data) of the oncogenes MYC (g) and KRAS (h) in selected CCLE cell lines. In (g), small cell lung cancer lines are indicated in red to highlight a subset potentially derived from MYC-driven tumors (within red box). (28) . Together with the ORPs OSBP, OSBPL3, and OSBPL10, the other candidate determinants, PLEKHO1 and THEM4, have also been implicated in PI3K/AKT signaling (27, 31) . Plots and analyses in panels b -d are based on non-hematopoietic GDSC cell lines. 
